[Neoadjuvant CYVADIC (cyclophosphamide, vincristine, adriamycin and dacarbazine) therapy for retroperitoneal leiomyosarcoma: a case report].

Abstract

Retroperitoneal leiomyosarcoma is often too large to be completely removed. We report a 67-year-old woman successfully treated with neoadjuvant CYVADIC (cyclosphosphamide, vincristine, adriamycin and dacarbazine). The tumor was removed with the right kidney and ureter and a part of the vena cava after 2 courses of CYVADIC. The tumor recurred at the duodenum 7 years later and was completely removed following neoadjuvant CYVADIC. Neoadjuvant chemotherapy could be helpful for the complete resection of advanced leiomyosarcoma.

• Authors: T Kamba, M Kawakita, T Noguchi, T Kamoto, T Okabe, E Takeuchi, M Matsumoto
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 43 Issue 8 Pg. 577-80 (Aug 1997) ISSN: 0018-1994 [Print] Japan
• PMID: 9310781 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Vincristine
• Dacarbazine
• Doxorubicin
• Cyclophosphamide

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant
• Cyclophosphamide (administration & dosage)
• Dacarbazine (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Leiomyosarcoma (drug therapy, surgery)
• Retroperitoneal Neoplasms (drug therapy, surgery)
• Vincristine (administration & dosage)